• SOURCE
    April 4, 2016
    The clinical trial found that end-stage heart failure patients treated with stem cells harvested from their own bone marrow had 37 percent fewer cardiac events than those who received a “dummy” placebo.”For the last 15 years, everyone has been talking about cell therapy and what it can do. These results suggest that it really works,” study author and cardiac surgeon Dr.Amit Patel, director of Cardiovascular Regenerative Medicine at the University of Utah School of Medicine in Salt Lake City, said in a university news release.Another expert was cautiously optimistic about the results.

    While the findings are promising, “further long-term data — and hopefully improved levels of heart efficiency and performance — would still need to be seen,” said Dr.David Friedman, chief of heart failure services at Northwell Health Long Island Jewish Valley Stream Hospital.

    In heart failure, a weakened or damaged heart no longer pumps blood the way it should. This potentially fatal disease affects about 5.7 million Americans, according to the American Heart Association.

    The new study involved 126 heart failure patients. Sixty received the stem cell treatment, while the other 66 got a placebo.

    After one year, 4 percent of the stem cell therapy patients had died and about 52 percent had been hospitalized for heart failure. That was an improvement on the group receiving the placebo, where 8 percent of patients died and more than 82 percent ended up in the hospital, Patel’s team said.

    “This is the first trial of cell therapy showing that it can have a meaningful impact on the lives of patients with heart failure,” Patel added.

    If further studies are successful, stem cell therapy may one day offer an alternative to current treatments for end-stage heart failure, such as heart transplantation and left ventricular assist device therapy, the researchers said.

    The study was published online April 4 in The Lancet journal and presented simultaneously at the annual meeting of the American College of Cardiology (ACC) in Chicago.

    There was other potentially good news from the ACC meeting for heart failure patients. On Sunday, a 10-year study led by researchers at Duke University found that bypass surgery plus medication appears to work better for heart failure patients, compared to the use of medications alone.

    The study involved more than 1,200 patients with severe heart disease and heart failure who were tracked for about a decade. All of the patients got standard heart drugs, but those who also underwent coronary bypass lived a median of 16 months longer. They also suffered fewer heart attacks, strokes and hospitalizations, the study found.

    “This now demonstrates that the advantages of [bypass] are robust and durable and the procedure saves and extends lives,” study author Dr. Eric Velasquez, heart failure specialist at the Duke Clinical Research Institute in Durham, N.C., said in a university news release.

     

     
     

    No comments

    Be the first one to leave a comment.

    Post a Comment


     

     

    Latest Posts

    Latest Video

     
     

    LATEST POSTS

    First FDA Approval For Clinical Cloud-Based Deep Learning In Healthcare

     SOURCE: FORBES The first FDA approval for a machine learning application to be used in a clinical setting is a…

    FDA-approved study uses adipose stem cells for treatment of shoulder injuries

    SOURCE Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose…

    Could Anatomics BioModel Stereotaxy replace navigation or a robot?

    SOURCE Paul S D’Urso Neurosurgeon & Founder of Anatomics Because 3D printing is so accurate I was able to locate…

    $250 million awarded to new Advanced Robotics Manufacturing Innovation Hub

    SOURCE Headquartered in Pittsburgh, PA, the new institute is made up of governments, industry, academia, and non-profit organizations from across the country….

    Self-assembling 3D printing inks produce more true-to-life tissue

    SOURCE Biological and chemical researchers are developing 3D printable inks capable of self-assembly, i.e. forming a shape based on a…

    Urine Exosomes – An Emerging Trove of Biomarkers

     SOURCE Exosomes are released by most cells and can be isolated from all biofluids including urine. Exosomes are small vesicles…

    What is machine learning?

    SOURCE In this fascinating animation from Oxford Sparks, we take a look at how statistics and computer science can be used to…

    Catalia Health uses social robots to improve health outcomes

    Credit: Catalia Health SOURCE Catalia Health is leading the surge in social robotics, with Mabu, their patient care management system. Catalia…